Company intelligence / Profile preview

LDS

Israel

Ownership: Private
Development stage: Other

Overview

LDS has developed proprietary drug delivery systems leveraging molecularly engineered liquid-structured nano-domains, which enhance bioavailability, stability, and release profiles of both small and large molecules. Technology is in clinical use via licensing and partnerships, with several programs progressing through clinical studies and commercialization.

Therapeutic areas: OtherOphthalmologyDermatology
Modalities: Small moleculeBiologicRecombinant proteinPeptidesNanoparticleAntibody
Industry: Drug Discovery Services

Partnerships

Global pharmaceutical, nutraceutical, and cosmeceutical companies

Beyond the preview

Go deeper on LDS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LDS.

Explore the full profile